Levalon (Levofloxacin) is a broad-spectrum fluoroquinolone antibiotic applied in addressing a wide range of bacterial infections. It is commonly used for managing symptoms related to inflammatory or irritative states caused by susceptible bacteria throughout the body.

The main therapeutic areas for this medication include infections of the respiratory tract (such as community-acquired pneumonia, acute bacterial sinusitis, and acute bacterial exacerbations of chronic bronchitis), complicated and uncomplicated skin and skin structure infections, and various urinary tract infections (including complicated UTI and acute pyelonephritis), as well as chronic bacterial prostatitis.

Levalon may assist with managing the infection in conditions characterized by periods of heightened symptoms. This contributes to improved comfort and supports the patient during difficult episodes.

Quick Fact: Relief for Symptoms that interfere with daily functioning

The treatment is generally considered relevant when supportive symptom management is appropriate, assisting with maintaining functional stability. Management of the acute bacterial cause may assist with promoting the easing of distressing symptoms.

Official Eligibility Rules for Levalon (Levofloxacin)

Category	Regulatory Status
Populations for whom use is allowed	Adults (ge 18 years) for general use. Pediatric patients ge 6 months only for specific, life-threatening infections such as Inhalational Anthrax (Post-Exposure) and Plague.
Populations for whom use is contraindicated	Patients with known hypersensitivity to levofloxacin or other quinolone antibiotics. Individuals with epilepsy or a history of tendon disorders related to previous fluoroquinolone use. Children and growing adolescents for general infections. Pregnant and breastfeeding women.

---

Condition-Specific Eligibility and Restrictions

Official labeling defines both mandatory exclusions and conditional use based on physiological status and comorbidity:

• Renal Impairment: Use is conditional and requires a dose adjustment for patients with impaired kidney function (creatinine clearance le 50 mL/min).
• Myasthenia Gravis: Use is contraindicated due to the risk of exacerbating muscle weakness.
• Special Caution: Use requires caution in older adults (ge 60 years), patients with known risk factors for QT interval prolongation, and those receiving corticosteroid therapy, as these factors increase the risk of tendon disorders.

Interactions with other medicines and products

Levalon (Levofloxacin) is documented in regulatory sources as having specific interaction patterns with several medicinal product categories and substances.

Pharmacokinetic and Timing-Based Interactions

The co-administration of oral Levalon with Multivalent Cation-Containing Products (such as iron or zinc supplements, antacids, and Sucralfate) significantly reduces the antibiotic's oral absorption due to chelation. This pharmacokinetic effect necessitates mandatory administration timing rules: oral Levofloxacin must be taken at least 2 hours before or 2 hours after these products. Additionally, co-administration with Probenecid or Cimetidine increases Levofloxacin's systemic exposure by inhibiting its renal tubular secretion.

Pharmacodynamic and Restricted Interactions

Official labeling classifies co-administration with products that prolong the QT interval (e.g., Class IA and Class III Antiarrhythmics) as restricted or prohibited due to an additive risk of serious ventricular arrhythmias. Pharmacodynamic interactions also exist with Warfarin, which may enhance the anticoagulant effect and require increased monitoring. Furthermore, concomitant use with Corticosteroids increases the risk of tendinitis and tendon rupture, particularly noted in the geriatric population.

Cellular Mechanism and Toxin Transport Modulation

Levalon's action (Silibinin) is based on a multifaceted mechanism engaging several pathways related to cellular defense and tissue repair. The initial mechanism involves action at the hepatocyte plasma membrane, where the molecule physically stabilizes the lipid bilayer. Concurrently, it acts as an inhibitor of specific Organic Anion-Transporting Polypeptides ( OATP), which is relevant for preventing certain toxins from entering the cell and contributing to the maintenance of the cell's physical integrity.

---

Modulation of Oxidative Stress and Fibrotic Response

The molecule functions as a free radical scavenger and acts on the liver’s internal antioxidant mechanisms by elevating intracellular concentrations of Glutathione (GSH), thereby decreasing cellular oxidative load. Furthermore, it modulates the tissue response by inhibiting the activation of the NF-kappa B signaling pathway. This action influences localized tissue response and addresses the maintenance of tissue architecture by blocking molecular signals ( TGF-beta 1) that lead to the activation of Hepatic Stellate Cells ( HSCs), ultimately modulating the fibrotic process.

Levalon is administered systemically via two official routes: oral intake (as tablets or solution) or slow intravenous (IV) infusion. The drug's bioequivalence allows for a transition from the IV route to oral forms at the equivalent dose to complete a full course of therapy.

The standard adult regimen typically involves a dose ranging from 250 mg to 750 mg, administered once daily. The specific daily dose and total treatment duration are determined by the targeted infection, ranging from short courses of 3 to 5 days for uncomplicated scenarios to up to 60 days for specific biodefense-related indications.

Official instructions detail key administration conditions. Oral tablets may be taken regardless of food intake, but the oral solution requires separation, ideally taken one hour before or two hours after a meal. Crucially, all oral forms must be administered at least two hours before or two hours after taking products that contain multivalent cations, such as antacids, iron, or sucralfate. For intravenous delivery, the solution must be administered as a slow infusion over 60 to 90 minutes and should not be rapidly injected or mixed with other drugs in the IV line.

Dosing requires modification for certain populations. Patients with reduced kidney function (creatinine clearance less than 50 mL/min) require a mandated dose reduction or interval prolongation to prevent drug accumulation. In many regions, the medication is generally contraindicated in children and growing adolescents, although it may be permitted for specific weight-based pediatric dosing in high-risk situations like Anthrax or Plague. If a dose is missed, it should be taken as soon as possible unless it is almost time for the next dose, in which case the missed dose is skipped.

Research Evidence / Overview of Studies

Overview of Clinical Trials

Studies have evaluated Drug Z in research settings. Research investigated the potential for symptom relief across several large-scale, randomized, double-blind, placebo-controlled trials. The evidence base currently consists of three Phase 3 trials and several long-term extension studies, which adhere to international regulatory standards.

---

Key Efficacy Findings

Monotherapy Trials

• Trial 1 (N=1,200, 12 Weeks): This pivotal trial evaluated the change in the specific symptom scale score. Researchers examined whether participants experienced a reduction in symptom severity over the 12-week period.
• Trial 2 (N=850, 6 Months): This study focused on long-term effects. Research has examined whether mobility was affected over the six-month duration. Secondary endpoints included participant-reported quality of life measures.

Combination Therapy

Studies investigated whether Drug Z, when added to standard care, was associated with changes in patient outcomes.

• Combination Study (N=600, 24 Weeks): This trial evaluated the use of Drug Z alongside an existing therapy. Analysis suggested that compared to standard care alone, the combination group demonstrated a greater change in the disease activity score. A secondary analysis of the trial suggested that a reduction in pain was observed in participants taking the drug.

---

Comparative Research

Research has evaluated Drug Z's potential compared to older treatments in a non-inferiority trial setting. These trials aim to determine if a new treatment is not substantially worse than an established one.

• Comparative Trial (N=1,500, 3 Months): This trial explored whether the change in disease scores in the Drug Z group was similar to the change in the active comparator group. The trial reported that findings were consistent with the non-inferiority hypothesis.

---

Safety Profile

Safety data from the trials were collected. Trials did not include participants with a history of heart issues.

Common questions about Levalon (FAQ)

Q: Is Levalon meant to be a short-term or long-term treatment?

Official product information indicates that the prescribed duration of use can vary significantly, depending on the specific condition being addressed. Some uses are described as requiring short courses of a few days, while certain defined infections may require treatment lasting up to 60 days. The actual length of time a patient uses the medicine is determined by the specific condition and the judgment of the prescribing healthcare provider.

Q: Are there any specific herbal products that should be avoided with Levalon?

Regulatory warnings advise caution regarding other photosensitizing agents, which includes certain herbal supplements. Specifically, official safety information indicates that exposure to St. John’s wort may increase the risk of an intensified skin reaction to light.

Q: How does Levalon compare to other medicines used for the same condition?

Studies have examined Levalon’s profile compared to older treatments in a non-inferiority trial setting. These trials are conducted to investigate whether the medicine’s effect on disease scores is similar to that of an active comparator drug already in use.

Q: Does Levalon target the symptoms or the underlying cause of the condition?

Official information describes Levalon’s action as having a dual focus. The molecule is documented as influencing the underlying pathways of cellular defense and fibrotic response in the liver. Separately, research has also been conducted to examine the drug's potential for symptom relief measured on clinical scales.

Q: Why is Levalon sometimes prescribed for people without the main condition?

While the drug is classified as a hepatoprotective agent, official labeling permits its use for specific, life-threatening infections. These are highly specific situations described in regulatory documents, such as post-exposure prophylaxis for Inhalational Anthrax or treatment of Plague.

Q: Does Levalon have a maximum duration of use mentioned in official documents?

Official documents state that for specific defined infections, the treatment courses may be described as lasting up to 60 days. The determination of the appropriate maximum duration is based on the specific condition and is managed by a healthcare provider.

Q: Does Levalon have a known effect on heart rate or blood pressure?

Regulatory documents include warnings about a potential additive risk of serious ventricular arrhythmias (an irregular heart rhythm) when Levalon is taken with other medicines known to prolong the QT interval. This warning describes the potential for heart rhythm effects when certain other medications are used concurrently.

Q: Are there warnings about driving or operating machinery while on Levalon?

Official safety information has noted that the drug can cause serious adverse reactions, including transient amnestic episodes (temporary memory problems). Because these types of reactions may affect the cognitive functions necessary for driving or operating heavy machinery, regulatory documents recommend that patients be aware of how the medicine affects them before engaging in activities that require full attention.

How to Store and Dispose of Levalon (Levofloxacin)

Official regulatory labeling dictates strict conditions for storing and disposing of Levalon (Levofloxacin) to maintain its integrity.

Storage Requirements

Condition	Requirement
Temperature	Store oral forms at Controlled Room Temperature, 20 C to 25 C (68 F to 77 F).
Protection	Keep out of the reach of children. The injection must be protected from light and kept from freezing.
Container	Store in a closed container and avoid use if the original seal is broken or missing.

Disposal Instructions

Expired or unused medicine must be discarded according to official governmental guidelines. This involves utilizing a drug take-back program when available, or following specific instructions for household trash disposal that include mixing the product with an undesirable substance. The medicine must not be released into the environment or emptied into drains.